Poly(A) Tail Length of Messenger RNA Regulates Translational Efficiency of the Mitochondria-Targeting Delivery System
Source abstract
Abstract
Mitochondria are essential for cellular functions, such as energy production. Human mitochondrial DNA (mtDNA), encoding 13 distinct genes, two rRNA, and 22 tRNA, is crucial for maintaining vital functions, along with nuclear-encoded mitochondrial proteins. However, mtDNA is prone to somatic mutations due to replication errors and reactive oxygen species exposure. These mutations can accumulate, leading to heteroplasmic conditions associated with severe metabolic diseases. Therefore, developing methodologies to improve mitochondrial health is highly demanded. Introducing nucleic acids directly into mitochondria is a promising strategy to control mitochondrial gene expression. Messenger RNA (mRNA) delivery especially offers several advantages such as faster gene expression and reduced risk of genome integration if accidentally delivered to the cell nucleus. In this study, we investigated the effect of the poly(A) tail length of mRNA on the mitochondrial translation to achieve efficient expression. We used a peptide-based mitochondrial targeting system, mitoNEET-(RH) 9, comprising a mitochondria-targeting sequence (MTS) and a cationic sequence, to deliver mRNA with various poly(A) tails into the mitochondria. The poly(A) tail length significantly affected translational efficiency, with a medium length of 60 nucleotides maximizing protein expression in various cell lines due to enhanced interaction with mitochondrial RNA-binding proteins. Our findings highlight the importance of optimizing poly(A) tail length for efficient mitochondrial mRNA translation, providing a potential strategy for improving mitochondrial gene therapy. These results pave the way for further exploration of the mechanisms and clinical applications of mitochondrial mRNA delivery systems.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Mitochondrial Function and Pathology · ATP Synthase and ATPases Research · RNA and protein synthesis mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biomacromolecule Research Team, RIKEN Center for Sustainable Resource Science, Wako-shi, Saitama 351-0198, Japan
Institute for Advanced Biosciences, Keio University, Tsuruoka-shi, Yamagata 997-0017, Japan.
Department of Material Chemistry, Kyoto University, Kyoto-shi, Kyoto 606-8501, Japan
Funding
Ministry of Education, Culture, Sports, Science and Technology · Japan Society for the Promotion of Science · Japan Science and Technology Agency
References (43)
Show source-provided references
1. 10.1038/s41556-018-0124-110.1038/s41556-018-0124-1 ↗
2. 10.1038/s41392-023-01547-910.1038/s41392-023-01547-9 ↗
3. 10.1038/290457a010.1038/290457a0 ↗
4. 10.1093/nar/gkaa101110.1093/nar/gkaa1011 ↗
5. 10.1016/j.cmet.2024.04.01210.1016/j.cmet.2024.04.012 ↗
6. 10.1146/annurev-biochem-060408-09370110.1146/annurev-biochem-060408-093701 ↗
7. 10.1016/j.bbagrm.2011.11.00510.1016/j.bbagrm.2011.11.005 ↗
8. 10.1038/nrg396610.1038/nrg3966 ↗
9. 10.1038/nrdp.2016.8010.1038/nrdp.2016.80 ↗
10. 10.1038/nrg160610.1038/nrg1606 ↗
11. 10.1002/ana.2436210.1002/ana.24362 ↗
12. 10.1016/j.addr.2020.09.01010.1016/j.addr.2020.09.010 ↗
13. 10.1021/acsbiomaterials.1c0111410.1021/acsbiomaterials.1c01114 ↗
14. Yu H. · Mol Vis · 2013 · 19 · 1482
15. 10.1021/acs.biomac.6b0105610.1021/acs.biomac.6b01056 ↗
16. 10.1016/j.biomaterials.2017.05.01610.1016/j.biomaterials.2017.05.016 ↗
17. 10.1016/j.jconrel.2018.02.00510.1016/j.jconrel.2018.02.005 ↗
18. 10.1002/adma.20210330710.1002/adma.202103307 ↗
19. 10.1002/adfm.20230607010.1002/adfm.202306070 ↗
20. 10.1073/pnas.111679210910.1073/pnas.1116792109 ↗
21. 10.1038/s41598-020-64322-810.1038/s41598-020-64322-8 ↗
22. 10.1038/s41580-021-00332-210.1038/s41580-021-00332-2 ↗
23. 10.1038/s41576-022-00480-x10.1038/s41576-022-00480-x ↗
24. 10.1021/mp400353n10.1021/mp400353n ↗
25. 10.1016/j.colsurfb.2016.08.03510.1016/j.colsurfb.2016.08.035 ↗
26. 10.3390/pharmaceutics1404088110.3390/pharmaceutics14040881 ↗
27. 10.1016/j.ymgmr.2020.10068710.1016/j.ymgmr.2020.100687 ↗
28. 10.1128/MCB.25.15.6427-6435.200510.1128/MCB.25.15.6427-6435.2005 ↗
29. 10.1101/2021.08.29.45807210.1101/2021.08.29.458072 ↗
30. 10.1021/ja506194z10.1021/ja506194z ↗
31. 10.1021/acsami.3c1260410.1021/acsami.3c12604 ↗
32. 10.1002/smsc.20230025810.1002/smsc.202300258 ↗
33. 10.1016/j.bbagrm.2011.10.01210.1016/j.bbagrm.2011.10.012 ↗
34. 10.3390/ijms23231516610.3390/ijms232315166 ↗
35. 10.1038/s43018-020-00112-510.1038/s43018-020-00112-5 ↗
36. 10.1016/S0047-6374(01)00328-110.1016/S0047-6374(01)00328-1 ↗
37. Nagao A. · 2008 · 447 · 489
38. 10.1093/nar/gks50610.1093/nar/gks506 ↗
39. 10.1016/j.celrep.2023.11303310.1016/j.celrep.2023.113033 ↗
40. 10.1038/s41467-017-01221-z10.1038/s41467-017-01221-z ↗
41. 10.1261/rna.052365.11510.1261/rna.052365.115 ↗
42. 10.1080/15384101.2015.105367210.1080/15384101.2015.1053672 ↗
43. 10.1016/j.celrep.2015.01.03010.1016/j.celrep.2015.01.030 ↗